Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Executive Summary

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Advertisement

Related Content

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds
Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services
Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
With Back-To-Back FDA Holds, Solid Hopes To Regain Footing For Duchenne Candidate
TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns
Big Pharma Outbids Public Investors: Step-Ups in Biopharma Exits

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel